Telix has extended its agreement with Endocyte, Inc.

Company News

by Rachael Jones

Biopharmaceutical company Telix Pharmaceuticals (ASX:TLX) has extended its agreement with Endocyte, Inc.

The company has amended its contract with Endocyte in relation to providing prostate cancer imaging technology for their phase III trial.

This contract amendment further extends access to their kit and technical support to select European jurisdictions, and to the United States.

The Endocyte VISION trial is an international, prospective, open-label, multicentre, randomised phase III study for the treatment of patients with progressive prostate cancer.

Shares in Telix Pharmaceuticals (ASX:TLX) closed 1.49 per cent higher to 68c yesterday

Rachael Jones

Finance News Network
Rachael comes to FNN after working for Fairfax Media covering international breaking news, including the global economy and politics. She joined FNN in February 2018. She has reported on Australia’s finance news for various organisations since 2000 and has also interviewed a number of key business players, including Bill Gates. Rachael has also worked across a number of countries, including the UK and the US.